An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy